The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
 
Rosa Maria Nadal
No Relationships to Disclose
 
Amir Mortazavi
Consulting or Advisory Role - Genentech/Roche
 
Mark Stein
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Nicole N. Davarpanah
No Relationships to Disclose
 
Howard L. Parnes
No Relationships to Disclose
 
Yang-Min Ning
No Relationships to Disclose
 
Lisa M. Cordes
No Relationships to Disclose
 
Mohammadhadi H. Bagheri
No Relationships to Disclose
 
Liza Lindenberg
No Relationships to Disclose
 
Ryan Thompson
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Tina Moore
No Relationships to Disclose
 
Tiffany Lancaster
No Relationships to Disclose
 
Milisyaris Velez
No Relationships to Disclose
 
Esther Mena
No Relationships to Disclose
 
Rene Costello
No Relationships to Disclose
 
Donald Bottaro
No Relationships to Disclose
 
William L. Dahut
No Relationships to Disclose
 
Andrea B. Apolo
No Relationships to Disclose